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Purpose. To report favorable outcome of a case of acute posterior multifocal placoid pigment epitheliopathy (APMPPE) associated
with cerebral vasculitis after treatment with immunosuppressive therapy by mitoxantrone. Design. Single case report. Method.
A 22-year-old man presented with acute isolated bilateral loss of vision revealing APMPPE. Corticosteroid therapy was initiated
and visual acuity gradually improved. Seventeen days later, visual function deteriorated again, associated with ﬂu-like syndrome
and severe headaches. A relapse of APMPPE was diagnosed, complicated with lymphocytic meningitis and cerebral ischemia.
Intravenous therapy with mitoxantrone was performed in combination with methylprednisolone. Results. Headaches disappeared
in a few days whereas visual acuity gradually improved and stabilized at 20/40 in the right eye and 20/32 in the left eye. No adverse
event was observed. Clinical improvement was conﬁrmed by magnetic resonance imaging. Conclusion.C e r e b r a lv a s c u l i t i si st h e
most severe complication of the extraocular manifestations of APMPEE. This diagnosis should be evoked when severe headaches
or behavior disorder are associated with APMPEE.
Copyright © 2009 H´ el` ene Mass´ e et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Acute posterior multifocal placoid pigment epitheliopathy
(APMPPE)wasﬁrstdescribedbyGass[1]asmultiplecreamy
white lesions at the level of the retinal pigment epithelium
with rapid loss of central vision and spontaneous recovery
within two to three weeks. The disorder invariably aﬀects
both eyes with preponderance for young adults. Choroidal
vasculitis has been proposed as the underlying pathological
process [2]. Since the initial report, systemic abnormalities
have been described in association with APMPPE includ-
ing polyarteritis and systemic necrotizing vasculitis with
Wegener’s granulomatosis [3]. Cerebral vasculitis is rare
but potentially and rapidly fatal [4]. We report a case
of APMPPE-associated cerebral vasculitis with favorable
outcome after treatment with immunosuppressive therapy
by mitoxantrone.
A 22-year-old man presented with sudden isolated
bilateral visual loss. He had no previous medical history. The
initial visual acuity was limited to counting ﬁngers at a dis-
tance of 50cm in both eyes. Fundus examination disclosed a
mild vitreous haze and multiple yellow-white placoid lesions
involving the retinal pigment epithelium in both posterior
poles. Characteristic hypoﬂuorescence in the early phase of
the angiogram followed by late hyperﬂuorescence of the
lesionsconﬁrmedthediagnosisofAPMPPE(Figure 1(a)and
1(b)). Intravenous methylprednisolone was initiated, and
visual acuity gradually improved. Seventeen days later, the
patient experienced recurrence of visual loss associated with
ﬂu-like syndrome and severe headaches. Ophthalmologic
examination did not reveal obvious new retinal lesion.
Cerebro-spinal ﬂuid analysis showed lymphocytic pleiocy-
tosis. Magnetic resonance imaging (MRI) revealed bilateral
parieto-occipital infarcts (Figures 2 and 3). Alternative
diagnoseswereexcludedbyextensivelaboratoryandvascular
investigations. In collaboration with the neurologists, three
intraveinous infusions of 20mg mitoxantrone associated
once with 1g methylprednisolone and anticoagulation by
antivitamin K were performed during a nine-month period.
Headaches disappeared in a few days while visual acuity
gradually improved over 3 months stabilizing at 20/40 in the
right eye and 20/32 in the left eye. Clinical improvement was2 Case Reports in Medicine
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Figure 1: Fluorescein angiography of (a) right and (b) left eye demonstrates a diﬀuse staining of the placoid lesions in the late frames.
Figure 2:T2-weightedMRIshowingbilateralhyperintenseparieto-
occipital lesions.
Figure 3: Diﬀusion tensor MRI emphasizing bilateral ischemia of
parieto-occipital territories.
conﬁrmed by MRI showing regression of occipital lesions.
Cerebrospinal ﬂuid analysis was normalized. Treatment was
performedundercloseclinical,haematological,andechocar-
diographical monitoring. No adverse eﬀect was detected.
Systemic vasculitis associated with APMPPE has been
previously described. These associations provide support for
the choroid asbeing primarily involved by a diﬀusevasculitic
process that interrupts choroidal perfusion and causes the
characteristic fundus ﬁndings in APMPPE.
Because of the potential severity of cerebral involvement
associated with APMPPE, immunosuppressive therapy, such
as cyclophosphamide, is usually considered. However, side
eﬀects of this drug are signiﬁcant, especially in young
adults,inparticulartransitoryordeﬁnitiveamenorrhoeaand
azoospermia.
Mitoxantrone, a synthetic anthracedione, is an estab-
lished cytotoxic, antineoplastic agent, now approved in
the treatment of multiple sclerosis [5]f o ri t sp r e s u m e d
mechanism of immunosuppression. The drug was generally
well tolerated at the recommended dosage [6], although
potential cardiotoxicity limits the total cumulative dose and
requires strict echocardiographical monitoring.
To the best of our knowledge, there is no mention
in literature of previous report relating prescription of
mitoxantrone in this indication. In cases of diﬀuse cerebral
vasculitis,thistreatmentcouldbeconsideredasatherapeutic
alternative.
Cerebral vasculitis is the most severe complication of the
extraocular manifestations of APMPEE. Although rare, this
complication can be fatal. Hence the diagnosis should be
evoked without delay when severe headaches or behavior
disorders are associated with APMPPE.
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